Sign in Subscribe
Cancer

Gene Therapy Shows Promise in Treating Laryngeal Cancer

Strategic Insights

— 1 min read

Researchers in Chengdu, People's Republic of China, have made significant breakthroughs in the treatment of laryngeal squamous cell carcinoma (LSCC) using a novel therapeutic strategy involving signal transduction interference therapy. By constructing recombinant adenoviruses Ad-p14(ARF) and Ad-antisense EGFR, the team successfully inhibited the proliferation of Hep-2 cells, inducing differentiation and apoptosis. The study's findings demonstrate the potential of combining Ad-p14(ARF) and Ad-antisense EGFR as a target for gene therapy in preventing human laryngocarcinoma cell proliferation.

Key Takeaways:

  • The researchers successfully constructed recombinant adenoviruses Ad-p14(ARF) and Ad-antisense EGFR using the AdEasy-1 vector system, which inhibited the proliferation of Hep-2 cells by up to 78.5, 77.7, and 86.9% for Ad-antisense EGFR, Ad-p14(ARF), and Ad-antisense EGFR + Ad-p14(ARF), respectively.
  • Clonogenic cell assay, western blotting assay, MTT assay, FCM assay, and immunocytochemical technique were used to examine the inhibition of proliferation, protein expression of p14(ARF) and EGFR, and induction of differentiation, respectively.
  • The activity of proliferation of Hep-2 cells was inhibited markedly by infecting Ad-p14(ARF) or Ad-antisense EGFR by comparing Ad-sense EGFR (P = 0.005) with vector control (Ad-Ctrl) (P = 0.005) and with PBS (P = 0.003).
  • The researchers observed p14(ARF) protein overexpression, EGFR protein downexpression, and inhibition of proliferation in Hep-2 cells infected by either Ad-p14(ARF) or Ad-antisense EGFR.
  • The proportion of apoptosis cells transfected by Ad-p14(ARF) and Ad-antisense EGFR increased more obviously than the control.
  • The researchers concluded that not only EGFR but p14(ARF) also plays a major role in the genesis and in modulating the cell growth and differentiation of human laryngocarcinoma.

Statistics:

  • 78.5% increase in proportion of (Hep-2 cells in) G(0)/G(1) phases in Ad-antisense EGFR.
  • 77.7% increase in proportion of (Hep-2 cells in) G(0)/G(1) phases in Ad-p14(ARF).
  • 86.9% increase in proportion of (Hep-2 cells in) G(0)/G(1) phases in Ad-antisense EGFR + Ad-p14(ARF).

Sources:

  • Xian, J.M., et al. "Signal transduction-related gene transfer leads to inhibition of proliferation and induction of differentiation in laryngeal squamous cell carcinoma in vitro." European Archives of Oto - Rhino - Laryngology, vol. 264, no. 12, 2007, pp. 1467-1473.
  • Health & Medicine Week editors. "Breakthroughs in Laryngeal Cancer Treatment." Health & Medicine Week, 2007.

Read more